Human Immunoglobulin for Clinical Use

Lane, R. S.; Vallet, L.; Kavanagh, Marianne; Welch, AnneG.; McIntosh, R. V.; Foster, Peter R.

doi:10.1016/s0140-6736(83)91662-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Igiv Products and Viral Hepatitis1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1983

1994

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical experience with IGIV products has been extensive, with millions of doses administered in the past 10 years. Early concerns about potentially increased risk from higher doses of IGIV products, relative to intramuscular immunoglobulins (200 to 1,000 mg/kg per infusion versus 100 mg/kg per injection), have not materialized (10,34,38). There are isolated exceptions to this general record of viral safety.…”

Section: Igiv Products and Viral Hepatitismentioning

confidence: 99%